Gaofeng Shi1, Qi Wang1, Hui Feng1, Hui Liu1, Mengyu Song1, Xinyue Liang2, and Yongming Dai2
1Department of Radiology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China, 2Central Research Institute, United Imaging Healthcare, Shanghai, China
Synopsis
Keywords: Quantitative Imaging, Cancer
Analysis of lymph node metastasis (LNM) in lung cancer
is vital for disease detection and treatment
planning optimization. Multi-parametric MRI was widely used not only to characterize tumor size and anatomy, but also to assess the tissue
metabolism and physiology. Conventionally, these are evaluated independently
and/or are combined into an average parameter for the entire tumor, while the spatial
information within the lesions was discarded. Habitat imaging allows to capture
these subtle differences in tumors. In this context, a multi-parametric MRI based
habitat analysis was approved to predict the LNM status.
Introduction
It has been well documented that lung adenocarcinoma (LUAD) is highly invasive, metastatic and
heterogenous.1 LNM is associated with poor prognosis
of tumor patients. The prognosis of patients with LNM is poorer than
those of patients without such
metastases (NLM). A key determinant of appropriate therapy for lung cancer
patients depends on the LNM status. Therefore, accurate assessment of LNM would
prove extremely useful in assessing prognosis and decisive for treatment
planning optimization in lung cancer.
Computed tomography (CT) and magnetic
resonance imaging (MRI) are commonly used for the LNM identification. However,
conventional CT and MRI focus on the morphological criteria, consensus diagnose
could sometimes be challenging. Positron emission
tomography (PET) is used for nodal staging assessment of NSCLC, while it is not widely available. Recently, a data-driven habitat
analysis as mapping subregions of the tumor with differential imaging
parameters has showed great potential in the detection of lung cancer and the
response to therapy. MRI offers a multidimensional characterization of lung cancer and yields insight into biophysical
properties. However, to the best of our knowledge, the multi-parametric
radiation-free MRI based habitats analysis for predicting the LNM status
remains unclear.
The aim of this study is to
predict LNM in LUAD patients using habitat analysis based on multi-parametric
MR imaging.Methods
This
retrospectively study examined LUAD patients who underwent chest MRI (3T, uMR780,
United Imaging Healthcare, Shanghai, China) with intravoxel incoherent motion
diffusion-weighted imaging (IVIM-DWI) (b = 0, 10, 20, 30, 50, 80, 100, 200, 400
and 800 s/mm2) and oxygen-enhanced MRI with ultrashort echo time
(OE-UTE). Based on the presence or absence of LNM, patients were divided into
the LNM group (n=13) and NLM group (n=38). IVIM data were processed according
to the following equation:2
Sb/S0 = (1-f)e-bD+fe-bD*(1)
where D was the
true diffusion coefficient; D* was the pseudodiffusion coefficient
representing perfusion-related diffusion; f was the perfusion fraction.
The percent
signal enhancement (PSE) map from OE-MRI of each patient was obtained with the voxel-wise
approach approved in Liu et al.3 Tumor volumes of interest (VOIs) were manually drawn slice by
slice by a radiologist with 10-years’ experience on T2W images. The voxels in
the VOIs from f maps and PSE maps were aggregated into different clusters using
the K-means clustering algorithm in Scikit-Learn python package. The tumor
volume and volume fraction of every
habitat were calculated and recorded as mean value with
standard deviation (SD). Mann-Whitney U test were used to assess the differences in fraction of the
subregions between different groups. The classification performance was compared
using the receiver operating characteristic (ROC) analysis with the area under
the curve (AUC). Results
Four
habitats were identified within the lesion: the normoxia habitat with high f and high PSE
(habitat 1), inflammatory habitat with low f and high PSE (habitat 2), the hypoxia
habitat with high f and low PSE (habitat 3), and the necrosis habitat with low f
and low PSE (habitat 4), respectively. The volume fraction of the
hypoxia habitat was higher in LNM group compared with NLM group ( and , P =
0.024). The AUC of the volume fraction of hypoxia habitat (AUC = 0.834) was
significantly higher than that of necrosis habitat (AUC = 0.686), normoxia
habitat (AUC = 0.789) and inflammatory habitat (AUC = 0.653) for LNM predicting.Discussion
Hypoxia and ischemia appear to be key elements in the tumor
progression, especially in metastasizing masses.4 Habitat analysis reflects subtly differences
within a tumor rather than the conventional approaches that average MRI
parameter for an entire lesion. With this study, the clinical
relevance of the volume fraction in hypoxia subregion using the multi-parametric MRI based habitat analysis was demonstrated to
identify the LNM status in LUAD.
Some limitations of this
study are needed to be addressed. First, patient population is relatively
small. Besides, the accuracy of the habitat’s segmentation by biopsy or
pathologic sampling was missing, however, unnecessary surgery should be avoided.Conclusion
In conclusion, a data-driven clustering approach is proposed to identify
tumor hypoxia subregion within LUAD tumors based on f maps and PSE maps from multi-parametric MRI.
The fraction of identified hypoxia habitat is a significant predictor of the presence or absence of
LNM in LUAD. Acknowledgements
None.References
1.Chen, Z.,
Fillmore, C. M., Hammerman, P. S., Kim, C. F. & Wong, K. K. Non-small-cell
lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14,
535-546, doi:10.1038/nrc3775 (2014).
2.Le Bihan, D. et al. Separation of diffusion and
perfusion in intravoxel incoherent motion MR imaging. Radiology 168, 497-505,
doi:10.1148/radiology.168.2.3393671 (1988).
3.Liu, H. et al. Pulmonary Functional Imaging for
Lung Adenocarcinoma: Combined MRI Assessment Based on IVIM-DWI and OE-UTE-MRI. Front Oncol 11, 677942, doi:10.3389/fonc.2021.677942 (2021).
4.Rundqvist, H. & Johnson, R. S. Hypoxia
and metastasis in breast cancer. Curr Top
Microbiol Immunol 345, 121-139,
doi:10.1007/82_2010_77 (2010).